ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- BioReliance Corporation
(Nasdaq: BREL) announced today that it has launched a global sales and
marketing organization, now offering its biologics testing and manufacturing
services on a comprehensive basis to clients around the world. This
reorganization follows BioReliance's acquisition of Q-One Biotech,
headquartered in Glasgow, Scotland, and represents a major step in
implementing the Company's post-acquisition strategy of serving its
international client base with global service offerings and support. The move
integrates a sales and marketing function that had been segmented regionally.
As a newly appointed vice president, Diana Morgan, Ph.D., 50, will now
lead the global sales and marketing organization from her offices in Glasgow,
Scotland and Rockville, Maryland. Dr. Morgan most recently had been the
Director of Sales for European Testing, Development and Manufacturing for
BioReliance. She joined the Company in 1994 following a successful career
spanning 14 years at The Beatson Institute for Cancer Research, where she
gained her doctorate, followed by a number of years as Laboratory Manager at
the Leukemia Research Fund Laboratory established by Professor David Onions,
one of the founders of Q-One Biotech. Key personnel from both the former
Q-One and BioReliance organizations join her team in this integration.
Capers W. McDonald, President and CEO, said, "This reorganization is part
of creating a more capable and global service enterprise. We are delighted
that Dr. Morgan will be leading us beyond the additive combination of our two
organizations to better serve the global marketplace. With approximately half
of our business now originating outside North America, we are fortunate to
have someone of Dr. Morgan's international experience in this newly created
position. We therefore view the initial costs of globalization -- relating
both to the acquisition of Q-One and the reorganization of our sales and
marketing -- as important investments that position us to provide a new level
of service in our competitive marketplace."
In accepting her new role, Dr. Morgan commented, "This opportunity is of
tremendous value to our current and prospective clients. Q-One has been an
outstanding service provider, and they are already complementing our growing
U.S. and U.K. operations.
"Quality, science and services that can be relied upon worldwide are key
parts of our strategy and a continuing pledge to our clients going forward.
These capabilities are continuing at all sites -- in Glasgow and Stirling in
the U.K., in Worcester and Rockville in the U.S., and in Heidelberg in
Dr. Morgan continued, "The combination of BioReliance and Q-One has
created an expanded, more vital service company. We now provide extended
resources and know-how to serve the needs of our customers. We are increasing
our range of services, since we plan the continued availability of Q-One
assays. We enjoy considerably greater capacities for scheduling client work,
enhancing timeliness while maintaining quality. We will continue both custom
and standard services, and can better source required services in the most
cost effective manner possible. The combination also will enhance multi-site
backup capabilities for many services."
The Company also announced that Ronald Baker, former Vice President of
Sales and Marketing in the U.S., has left the Company to pursue other
BioReliance Corporation is a leading, global contract service organization
providing integrated testing, development and manufacturing services for
biologics and other biomedical products to biotechnology and pharmaceutical
companies worldwide. The Company believes it is the largest provider of
outsourcing services focused on the expanding biologics sector of the
Certain statements made in this release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance, or
achievements, and may contain the words "believe," "anticipate," "confident,"
"expect," "estimate," "project," "will be," "will continue," "will likely
result," or similar words or phrases. Comments such as those with respect to
BioReliance's ability to integrate effectively and efficiently the operations
of Q-One Biotech, constitute forward-looking statements. As and when made,
management believes that these forward-looking statements are reasonable.
BioReliance undertakes no obligation to revise or publicly release the results
of any revision to these forward-looking statements. Forward-looking
statements involve risks and uncertainties, which may cause actual results to
differ materially from the forward-looking statements. Risks and
uncertainties are detailed from time to time in reports filed by BioReliance
with the Securities and Exchange Commission, including in its Forms 10-K and
10-Q. Given these risks and uncertainties, investors should not place undue
reliance on forward-looking statements as a prediction of actual results.
SOURCE BioReliance Corporation